According to Lilly (LLY.US) official Weibo message, Lilly China announced that Mulfonda ®(tilpositide injection) has been approved by the National Drug Administration (NMPA). This drug is an innovative once-weekly glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist suitable for the treatment of type 2 diabetes in adults with poor blood sugar control (hereinafter referred to as metformin and/or sulfonylurea) based on diet control and exercisepotioncommotion: T2DM) patients.
According to reports, Mofonda ®(tilpositide injection) can selectively bind and excite two natural incretin receptors, GIP receptor and GLP-1 receptor, reducing fasting and postprandial blood sugar levels in patients with T2DM. Mofonda ® is currently available in 4 strengths: 2.5 mgpotioncommotion:0.5ml，5 mg:0.5ml，7.5 mg:0.5ml，10 mg:0.5ml。This approval is mainly based on the global pivotal phase 3 registration trials SURPASS 1-5 in patients with T2DM and the Asia-Pacific pivotal phase 3 registration trial SURPASS-AP-Combo(83.4% of the subjects are Chinese patients).
The overall safety profile of Mulfonda ® in patients with T2DM in the Asia-Pacific region, which is dominated by the Chinese population, is consistent with the global population, and no new safety signals have been identified. Gastrointestinal reactions are the most common adverse reactions, usually occurring during the dose escalation period and decreasing over time, and are mostly mild or moderate in severity.